- VRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $355.1 million.
- VRX traded 12,601 shares today in the pre-market hours as of 9:29 AM.
- VRX is up 4.4% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in VRX with the Ticky from Trade-Ideas. See the FREE profile for VRX NOW at Trade-Ideas More details on VRX: Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Valeant Pharmaceuticals International has been 2.4 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $39.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.96 and a short float of 5.5% with 4.55 days to cover. Shares are down 1.2% year-to-date as of the close of trading on Tuesday.
- VRX's very impressive revenue growth greatly exceeded the industry average of 4.7%. Since the same quarter one year prior, revenues leaped by 86.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
- VALEANT PHARMACEUTICALS INTL reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, VALEANT PHARMACEUTICALS INTL reported poor results of -$2.62 versus -$0.38 in the prior year. This year, the market expects an improvement in earnings ($8.00 versus -$2.62).
- The debt-to-equity ratio is very high at 3.30 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with the unfavorable debt-to-equity ratio, VRX maintains a poor quick ratio of 0.92, which illustrates the inability to avoid short-term cash problems.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, VALEANT PHARMACEUTICALS INTL's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Valeant Pharmaceuticals International Ratings Report.